您的位置: 印度药房网 > 医药大数据 > 淋巴瘤 >
依鲁替尼

印度依鲁替尼

资料发布时间:2018-10-30 14:50:00 最后更新时间:2021-02-26 18:34:33

【药品简介】 依鲁替尼是一种小分子BTK抑制剂,能够与BTK活性中心的半胱氨酸残基共价结合,从而抑制其活性。

【适应症状】 依鲁替尼,白血病、淋巴瘤:慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤(CLL/SLL),以及带有17p缺失突变的CLL/SLL;用于治疗既往接受过治疗的套细胞淋巴瘤(MCL)

【 药品别名 】 依鲁替尼 Ibrutinib Emlutini

印度依鲁替尼(依鲁替尼 Ibrutinib Emlutini)价格,正品图片,治疗淋巴瘤药物, 购买依鲁替尼请到印度药房官方网站进行购买 【印度药房大全目录】

【 市场参考价格 】 ¥2120.00~2360.00

播放/暂停

【印度依鲁替尼说明书,怎么吃?】

依鲁替尼作用机制:

依鲁替尼(Ibrutinib)是小分子BTK 抑制药,与BTK活性位点中的半胱氨酸残基形成共价键,从而抑制BTK酶的活性。研究显示,依鲁替尼具有抑制恶性B细胞增殖和体内的存活以及体外细胞迁移和底物的黏附作用。
 
依鲁替尼
 
依鲁替尼参考用法:

1. CLL/SLL:口服,420mg 每天一次(单药或与苯达莫司汀/美罗华联用);直至疾病进展或不可接受的毒性。

2. CLL/SLL(含17p缺失):口服,420mg 每天一次;直至疾病进展或不可接受的毒性

3. 套细胞淋巴瘤,经治:口服,560mg 每天一次,直至疾病进展或不可接受的毒性

4. Waldenström macroglobulinemia:口服,420mg 每天一次,直至疾病进展或不可接受的毒性
 
依鲁替尼常见副作用:

头痛、劳累、早饱、恶心呕吐、腹痛、腹泻、便秘、肌肉痛、关节痛等

临床试验中,在接受过治疗的CLL患者中,总反应率为58.3%,缓解持续时间为5.6-24.2月;套细胞淋巴瘤,总反应率位65.8%,缓解持续时间为17.5月

依鲁替尼英文说明书

Ibrutinib uses

Ibrutinib is used in the treatment of mantle-cell lymphoma and blood cancer (chronic lymphocytic leukemia). It is also used in chronic lymphocytic leukaemia who have received at least one prior therapy or with 17p deletion.

How ibrutinib works

Ibrutinib is a Bruton's tyrosine kinase inhibitor. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Common side effects of ibrutinib

Headache, Joint pain, Fever, Diarrhea, Vomiting, Stomatitis (Inflammation of the mouth), Nausea, Constipation, Low blood platelets, Decreased white blood cell count (neutrophils), Upper respiratory tract infection

Ibrutinib

生物活性

产品描述

Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.

靶点活性

BLK,0.5 nM (cell free)

Bmx,0.8 nM (cell free)

BTK,0.5 nM (cell free)

CSK,2.3 nM (cell free)

FGR,2.3 nM (cell free)

BRK,3.3 nM (cell free)

实验溶液

2% DMSO+castor oil: 10 mg/mL

体外活性

In DOHH2, a cell line in which the BCR pathway can be activated by stimulation with anti-IgG, Ibrutinib (PCI-32765) inhibits autophosphorylation of Btk (IC50: 11 nM), phosphorylation of Btk's physiological substrate PLCγ (IC50: 29 nM), and phosphorylation of a further downstream kinase, ERK (IC50: 13 nM). Continuous exposure to 10 nM PCI-32765 for 18 h completely prevented up-regulation of the B-cell activation marker CD69. A 1-h pulse exposure to 10 nM PCI-32765 resulted in a similar level of CD69 inhibition in B cells [1]. PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50: 8 nM). Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 production in primary monocytes (IC50s: 2.6/0.5/3.9 nM). Following FcεRI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD(2), TNF-α, IL-8, and MCP-1 [2]. Treatment of CD40 or BCR activated CLL cells with PCI-32765 results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-κB. In addition, PCI-32765 inhibits activation-induced proliferation of CLL cells in vitro and effectively blocks survival signals provided externally to CLL cells from the microenvironment [3].

体内活性

PCI-32765 (3.125, 12.5, or 50 mg/kg per day) markedly inhibited clinical arthritis scores. Partial and nearly complete elimination of clinical signs of the disease occurred after 9 to 11 d of treatment at dosages of 3.125 and 12.5 mg/kg per day, respectively. An oral single dose of PCI-32765 at 3.125 mg/kg per day resulted in partial Btk occupancy in splenocytes, and the maximally efficacious dose (12.5 mg/kg per day) was sufficient to fully occupy Btk for 12 h [1]. PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model (ED50: 2.6 mg/kg/day). PCI-32765 also prevented clinical arthritis in CAIA models. In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited [2].

激酶实验

In vitro kinase IC50s were measured using 33P filtration binding assay after 1 h incubation of kinase, 33P-ATP, inhibitor, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays were performed at Reaction Biology [1].

细胞实验

CD20+ B and CD3+ T cells were purified by negative selection (RosetteSep, >90% purity) from buffy coat PBMCs and viably frozen in 10% DMSO. Cells were thawed at 37 °C and maintained in growth media (RPMI media containing 10% FCS). B cells were stimulated with goat anti-human IgM F(ab′)2 (10 μg/mL) and T cells were stimulated with anti-CD3/CD28 coated beads at a 1:1 bead/cell ratio. Cells were stained with PE-CD69 and analyzed by flow cytometry, gating on viable lymphocytes. PCI-32765 at concentrations lower than 10 μM did not decrease B- or T-cell viability during the course of the experiment, although PCI-32765 did block the modest survival benefit of anti-IgM stimulation in B cells. For washout experiments, cells were rinsed three times in 10 volumes of growth media, a protocol that was confirmed to completely wash away inhibition of BCR signaling by PCI-29732, a reversible Btk inhibitor [1].

细胞系: Chronic lymphocytic leukemia (CLL) cells

动物实验

ale DBA/1 mice were immunized with type II collagen plus Freund adjuvant and boosted 21 d later. On a rolling basis, as significant swelling appeared in at least one paw, mice were enrolled and randomized. PCI-32765 or dexamethasone (0.2 mg/kg) was administered orally once per day for 11 d. Arthritis scores (0–5) were assigned to the mice based on the degree and extent of paw swelling. Mouse anti-type II collagen antibody and total IgG levels were measured by ELISA. Female MRL/MpJ-Faslpr mice received PCI-32765 by oral gavage once per day from week 8 through week 20. Proteinuria was monitored weekly. At week 20, serum was collected and analyzed for BUN and mouse anti-dsDNA antibody levels. Kidney histology was scored according to established criteria (26). No drug-induced weight loss was observed at any of the dose levels tested. These studies were carried out at Boulder Biopath according to approved animal care protocols. Results are presented as the mean ± SEM. Statistical significance between groups were evaluated with repeated measures one-way ANOVA or one-way ANOVA using GraphPad Prism with Tukey or Bonferroni multicomparison posttest [1].

动物模型:MRL-Fas(lpr) lupus model and collagen-induced arthritis model.

化学信息

分子量

440.50

分子式

C25H24N6O2

CAS

936563-96-1

溶解度

DMSO: 82 mg/mL (186.2 mM)

Ethanol: <1 mg/mL

Water: <1 mg/mL

( < 1 mg/ml refers to the product slightly soluble or insoluble )

储存条件

store at -80°C

备注

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

配制溶液

  1 mg 5 mg 10 mg
1 mM 2.27 ml 11.351 ml 22.701 ml
5 mM 0.454 ml 2.27 ml 4.54 ml
10 mM 0.227 ml 1.135 ml 2.27 ml
50 mM 0.045 ml 0.227 ml 0.454 ml

注:本站依鲁替尼(依鲁替尼 Ibrutinib Emlutini)药品说明,价格,正品图片均来自于官方,依鲁替尼如何服用请尊医嘱。如需药品请到正规印度药房进行购买
上一篇:没有了 下一篇:没有了
依鲁替尼相关药品
依鲁替尼
依鲁替尼

白血病、淋巴瘤:慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤(CLL/SLL),以及带有17p缺失突变的CLL/SLL;用于治疗既往接受过治疗的...

依鲁替尼资讯
乐伐替尼的副作用需要明白
乐伐替尼的副作用需要明白

人类的悲欢不共通的,健康人永远无法理解癌症患者的痛苦一样,但无论痛苦有多严重,都无法偷走心中的幸福。痛苦和幸福都是重...

阿昔替尼的不良反应
阿昔替尼的不良反应

阿昔替尼被FDA批准可用于晚期肾细胞癌的一线治疗,那么使用阿昔替尼会怎样的不良反应呢? 数据显示,多数不良反应(蛋白尿、外...

舒尼替尼有很好的效果,提高患者的生存质量
舒尼替尼有很好的效果,提高患者的生存

舒尼替尼在我国已经上市很久了,舒尼替尼在国内被批准用于转移性肾癌,给很多肾癌患者带去了希望。舒尼替尼是一种络氨酸激酶...

卡博替尼的效果很好
卡博替尼的效果很好

卡博替尼的的作用靶点很多,PDA已经批准可用于甲状腺髓样癌、晚期肾癌的后线治疗、晚期肾癌的一线治疗和索拉非尼耐药的肝癌,...

拉帕替尼对于乳腺癌的效果
拉帕替尼对于乳腺癌的效果

随着如今医疗水平的不断提升,在乳腺癌治疗方面已经取得了很大的进步。其中拉帕替尼已获得中国国家食品药品监督管理局(CFDA)批...

乐伐替尼有这些不良反应
乐伐替尼有这些不良反应

乐伐替尼是抗癌药物,主要用于肝癌的治疗,有着非常好的效果,乐伐替尼的上市结束了肝癌患者耐药后无药可治的尴尬状况,为广...

服用色瑞替尼需要注意这些
服用色瑞替尼需要注意这些

肺癌是现在比较常见的恶性肿瘤,大家都应该重视起来,及时做好检查。而色瑞替尼在治疗肺癌方面有着很大的作用,通过合理的使...

克唑替尼的价格贵吗
克唑替尼的价格贵吗

克唑替尼作为口服的治疗肺癌药物,根据相关研究显示,克唑替尼具有非常好的耐受性。并且克唑替尼在临床上不良反应大多都为轻...

艾乐替尼的价格
艾乐替尼的价格

艾乐替尼经过美国FDA批准上市,主要是用来医治ALK阳性的转移性非小细胞肺癌。艾乐替尼于2018年12月在中国上市,药品名字为安圣莎...

吉非替尼的保质期
吉非替尼的保质期

吉非替尼是英国阿斯利康公司研制的治疗肺癌的药物,其主要用来医治之前接受过化学治疗的局部晚期或者转移性非小细胞肺癌的患...

依鲁替尼视频
索非布韦是什么原理治疗丙肝的?
索非布韦是什么原理治疗丙肝的?

丙肝治疗的药物,干扰素是通过它有一个免疫调节的作用来治疗丙肝...

吉三代的副作用
吉三代的副作用

吉三代的副作用:会有轻微的副作用,类似感冒的症状...

甲肝乙肝丙肝哪个严重?
甲肝乙肝丙肝哪个严重?

没法来说甲肝、乙肝、丙肝哪一个严重,因为还要根据发病的具体的情况来定...

丙肝患者能生孩子吗
丙肝患者能生孩子吗

北京华大中医医院讲解:丙肝患者怎么做才能生育健康宝宝。...

药房目录大全

Pharmacy Catalogue

  • 01印度Medicine Centre药房 印度Medicine Centre药房
    印度Medicine Centre药房


    【价格低廉】【有实体店】【在线客服】 【印度直邮】【有中文网站】【支持银联支付】

    Medicine Centre药房成立于1991年, 主要从事批发贸易和出口各种药物注射剂,药物胶囊和药物片剂。该药房的销售网...

  • 02印度MedPlus药房 印度MedPlus药房
    印度MedPlus药房


    【禁止中国访问】【印度连锁】【品牌实力】

    MedPlus是印度第二大药房连锁店。它经营1555家商店,其中1317家为公司所有,159家为特许经营公司,43家为医院药房...

  • 03印度Wellness Forever Medicare药房 印度Wellness Forever Medicare药房
    印度Wellness Forever Medicare药房

    【药品种类丰富】【渠道正规】【价格较高】

    Wellness Forever是一家生活方式零售药房连锁店,致力于为印度本土客户提供全面的健康服务。目前总收入约为620多...

  • 04印度Netmeds药房 印度Netmeds药房
    印度Netmeds药房


    【visa/万事达】 【全球可邮】【纯线上销售】【可开处方】

    Netmeds.com致力于开发印度本土市场,已成为印度领先的在线药店。Netmeds.com通过其全天候在线门户和移动应用程序...

  • 05印度Buy Drug药房 印度Buy Drug药房
    印度Buy Drug药房

     
     
    【】【】【万事达】

    Buy Drug Pharmacy™是一家零售药品连锁店,通过提供增值服务(如处方管理、船上药剂师处方的数字化、存储健康历...

  • 06印度1mg药房 印度1mg药房
    印度1mg药房


    【不支持海外邮购】【在线医疗诊断】【万事达卡】

    印度1mg药房,www.1mg.com...